Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

University of Osaka researchers used genome editing to program mouse liver cells to produce exenatide, a weight-loss drug.

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan ...

Researchers create a one-time genome editing introducing a GLP-1 receptor agonist, resulting in long-term appetite ...

Adults with type 1 diabetes on multiple daily injection therapy saw no benefit in glycemic measures when adding on preprandial injections of short-acting exenatide, according to findings from a ...

Exenatide is the active ingredient in BYETTA(R) (exenatide) injection, which is currently available in the U.S. and in many countries worldwide for people with type 2 diabetes who are unable to ...

Exenatide is a GLP-1-like (analog) medication primarily prescribed to treat Type 2 diabetes, approved by the U.S. Food and Drug Administration in 2005.

The Exenatide-PD3 trial randomly assigned 194 Parkinson's patients who were on dopaminergic treatment to either 2 mg of extended-release exenatide by subcutaneous pen injection once weekly (97 ...

Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to assess the pharmacokinetic and safety profile of its exenatide NanoPortal ...

Treatment with once-weekly exenatide was not associated with improvements in patients with Parkinson disease, according to findings from a study published in The Lancet.. Exenatide, a glucagon ...

A study in the United Kingdom involved 194 people with Parkinson’s disease who were randomly assigned to inject themselves once a week with exenatide, marketed as Byetta, or with a placebo.